Rhythm Biosciences announcement

Rhythm Biosciences Ltd (ASX: $RHY) has announced the establishment of its Clinical Advisory Board (CAB) to provide expert guidance and oversight for the further development process of the ColoSTAT® test kit. The CAB will ensure the accuracy, safety, and efficacy of the test, as well as its relevance in clinical practice and towards better patient experience and care.

Executive commentary

We are honoured to have world-class, distinguished leaders in their field of Colorectal Cancer diagnostics form our CAB and look forward to their expertise and guidance in this significant commercialisation stage of ColoSTAT®, commented Otto Buttula, Executive Chairman of Rhythm Biosciences.

Summary of Rhythm Biosciences announcement

Rhythm Biosciences (ASX: $RHY) has established a Clinical Advisory Board (CAB) comprising world-class specialists in Colorectal Cancer diagnostics to guide the further development process of the ColoSTAT® test kit. The CAB will ensure the accuracy, safety, and efficacy of the test, as well as its relevance in clinical practice and towards better patient experience and care. The company aims to achieve commercialization and distribution of these simple solutions to improve patient outcomes through early cancer detection. The establishment of the CAB marks a significant step in Rhythm Biosciences' mission to deliver a test for the early detection of Colorectal Cancer, ultimately reducing the global burden of cancer and saving lives.